Fitxers

843516.pdf (1.06 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2020-05-07

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/226143

Immune-related adverse events of checkpoint inhibitors

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41572-020-0160-6

Resum

Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or system. These effects are frequently low grade and are treatable and reversible; however, some adverse effects can be severe and lead to permanent disorders. Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the potential of short-term and long-term complications. Thoughtful management of irAEs is important in optimizing quality of life and long-term outcomes.

Matèries

Resposta immunitària, Immunoregulació, Efectes secundaris

Matèries (anglès)

Immune response, Immunoregulation, Side effects

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

RAMOS CASALS, Manuel, et al. Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers. 2020. Vol. 6, num. 1. ISSN 2056-676X. [consulted: 13 of May of 2026]. Available at: https://hdl.handle.net/2445/226143

Exportar metadades

JSON - METS

Compartir registre